Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nankai Univ. VEGFR-2 compound 9
- Development stage
- Unknown
- Lead developer
- Nankai University
01
Overview
Nankai Univ. VEGFR-2 compound 9: sourced facts only. name: "Compound 9 demonstrated notable anti-angiogenic activity in the zebrafish model, suggesting its potential as a VEGFR-2 inhibitor." [PMID:40939535]; target: "Compound 9 demonstrated notable anti-angiogenic activity in the zebrafish model, suggesting its potential as a VEGFR-2 inhibitor." [PMID:40939535]; developer: "State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy, and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Tianjin 300350, People's Republic of China." [PMID:40939535]; stage: "Compound 9 demonstrated notable anti-angiogenic activity in the zebrafish model, suggesting its potential as a VEGFR-2 inhibitor." [PMID:40939535]
02
Targets
VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on Nankai Univ. VEGFR-2 compound 9.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nankai Univ. VEGFR-2 compound 9.